US20260306649
2026-10-08
Human necessities
A61K47/68031
Methods are detailed for treating cancers, specifically unresectable locally advanced or metastatic urothelial cancer, using antibody drug conjugates (ADC) that bind to the 191P4D12 protein, known as Nectin-4, in combination with pembrolizumab. These methods target patients unable to undergo cisplatin-based chemotherapy.
Cancer remains a leading cause of mortality, particularly metastatic cancers, which often result in poor outcomes despite advanced treatment options. Novel strategies, including targeting specific molecular pathways, are essential for improving survival rates. Nectin-4, a transmembrane protein involved in cell-cell adhesion, is notably overexpressed in several cancers, including urothelial cancer, and correlates with disease progression.
Nectin-4, identified through bioinformatics, is upregulated in various cancers such as breast, lung, pancreatic, and ovarian cancers. Its expression is linked to poor prognosis. PD-1, a crucial molecule in immune regulation, interacts with PD-L1 and PD-L2, which are often expressed in cancers and associated with poor outcomes. Pembrolizumab, a monoclonal antibody, inhibits PD-1 interactions, enhancing immune response against tumors.
Pembrolizumab, marketed as Keytruda®, is a humanized IgG4 monoclonal antibody that blocks PD-1, preventing its interaction with PD-L1 and PD-L2, thereby enhancing T-cell activation. It is used in various cancer treatments, including first-line therapy for certain metastatic colorectal cancers, and is a standard of care for first-line treatment in specific cancer cases.
Urothelial cancer is a significant global health concern, with high incidence and mortality rates. It ranks as the ninth most common cancer worldwide, with substantial annual diagnoses and deaths reported in Europe, Japan, and the United States. The development of innovative therapies, such as those combining ADCs targeting Nectin-4 with pembrolizumab, is crucial for improving patient outcomes.